Objective: To investigate whether armillariella tabescens polysaccharides (ATPS) alleviates inflamma- tory responses and tissue damage in 5-fluorouracil ( 5-FU ) -induced chemotherapy-induced intestinal mucositis ( CIM) by inhibiting the TLR4 /MyD88 /NF-κB signaling pathway． Methods: Thirty 8-weeks-old male C57BL/6J mice were randomly divided into five groups ( n = 6 per group) : control group，model group ，and ATPS-treated groups (low，medium，high dose : 100，200，400 mg / kg) ．Body weight changes were recorded ; Disease activity in- dex (DAI) scores were evaluated ; small intestinal length and histopathology were measured ; HE staining and his- topathological scoring were performed ; immunohistochemistry was used to detect the expression of tight junction pro- teins (ZO-1，Occludin) in the small intestine ; serum levels of inflammatory cytokines interleukin-6 ( IL-6 ) and tumor necrosis factor-alpha (TNF-α) were analyzed by enzyme-linked immunosorbent assay (ELISA) kit ; Western blot was employed to quantify ZO-1，Occludin，and TLR4 /MyD88 /NF-κB pathway-related protein TLR4，MyD88，NF-κB p65，IκBα , p-NF-κB p65，p-IκBα protein expression． Results : Compared with the control group，mice in the model group exhibited significant reductions in body weight ，elevated DAI scores ，shortened small intestinal length，increased histopathological scores，marked downregulation of ZO-1 and Occludin expression，and elevated levels of inflammatory cytokines TNF-α and IL-6．Additionally，protein expression levels of TLR4，MyD88，p-NF- κB p65，and p-IκBα were significantly upregulated ( all P ＜0. 01 ) ． In contrast ，mice in ATPS-treated groups showed dose-dependent improvements，attenuated weight loss，reduced DAI scores，restored intestinal length，de- creased histopathological scores，upregulated ZO-1 and Occludin expression，reduced TNF-α and IL-6 levels，and downregulated TLR4，MyD88，p-NF-κB p65，and p-IκBα protein expression (all P＜0. 01) ． Conclusion ATPS alleviates 5-FU-induced CIM by inhibiting the TLR4 /MyD88 /NF-κB signaling pathway．

Whole brain radiotherapy (WBRT) is the standard radiotherapy regimen of preventive radiation for patients diagnosed with brain metastases and non-small cell lung cancer, which can improve intracranial control and prolong overall survival. However, neurocognitive functions (NCF) decline due to impaired hippocampal might occur thereafter. Recent studies have shown that hippocampal sparing WBRT (HS-WBRT) is capable of protecting neurocognitive function and improving quality of life (QOL). In this review, the authors described the methods and significance of hippocampal sparing, summarized the research progress on clinical trials related to HS-WBRT in combination with the development of radiotherapy technology and experimental drugs, and discussed the existing controversies and problems, aiming to provide reference for clinical work.

Objective: To investigate the reversal effect of cinobufagin ( CINO) combined with 5-fluorouracil (5- FU) on human colorectal cancer ( CRC) drug-resistant cell line HCT15 /5-FU，and to clarify the regulatory role of hypoxia-inducible factor-1α (HIF-1 α) / vascular endothelial growth factor (VEGF) pathway in reversing chemoresistance of colorectal cancer． Methods : MTT assay was used to detect the changes of drug resistance and drug resistance index，flow cytometry was used to evaluate the apoptosis of cells ，scratch test and Transwell assay were used to detect the changes of cell migration and invasion ability．Western blot was used to detect the expressions of epithelial-mesenchymal transition (EMT) related proteins and HIF-1 α/ VEGF pathway-related proteins. Results: Compared with HCT15 cells，the resistance index of HCT15 /5-FU was about 8. 720． CINO combined with 5-FU could significantly enhance the drug sensitivity of HCT15 /5-FU cells，reduce drug resistance index，up-regulate the level of apoptosis，and inhibit cell migration and invasion in a dose-dependent manner．Western blot results showed that CINO combined with 5-FU could inhibit the activity of EMT and HIF-1 α/ VEGF pathway． Conclusion CINO can reverse 5-FU resistance of colorectal cancer in vitro，and its mechanism may be related to the regulation of the HIF-1 α/ VEGF pathway and the inhibition of EMT and angiogenesis.

Objective: To compare the short-term efficacy and long-term survival rate of radical radiotherapy combined with concurrent chemotherapy and sequential chemotherapy in esophageal cancer patients, and to investigate the dominant population of esophageal cancer patients who were suitable for concurrent chemoradiotherapy. Methods: Two hundred and eighty patients with esophageal cancer treated with radical radiotherapy from July 2015 to June 2020 were recruited, including 140 patients with concurrent chemotherapy and 140 patients with sequential chemotherapy. The short-term efficacy and long-term survival rate between two groups were compared. Kaplan-Meier survival analysis, Logistic regression analysis and Cox regression analysis were used to analyze the risk factors for short-term efficacy, long-term survival rate and the dominant population suitable for concurrent chemoradiotherapy. Results: There was no significant difference about the short-term efficacy between the two groups(P>0.05), but in patients with TNM<Ⅳ, the complete remission(CR) rate in concurrent chemotherapy group(18.6%) was higher than that in sequential chemotherapy group(7.7%)(χ2=5.079,P=0.024). Among patients with midpiece esophageal cancer, CR rate in concurrent chemotherapy group was higher than that in sequential chemotherapy group(20.0%vs6.7%, χ2=4.498,P=0.034). The CR rate in patients with TNM<Ⅳ and midpiece esophageal cancer was higher in concurrent chemotherapy group(21.2%) than that in sequential chemotherapy group(2.2%)(χ2=7.459,P=0.006). Results of Kaplan-Meier survival analysis showed that the total survival time(4.0 years) and the 3-year survival rate(73.2%) in concurrent chemotherapy group were higher than those in sequential chemotherapy group(2.8 years, 24.2%)(P<0.000 1,P<0.000 1). Logistic regression analysis showed that patients with TNM<Ⅳ and midpiece esophageal cancer(OR=11.85) had higher CR rate in group with concurrent chemoradiotherapy(P<0.05). Cox regression analysis showed that concurrent chemoradiotherapy was a protective factor for death in patients with esophageal cancer(HR=0.448,P<0.000 1). Concurrent chemoradiotherapy was also a protective factor for death in patients with TNM<Ⅳ(HR=0.286), with midpiece esophageal cancer(HR=0.499), with midpiece esophageal cancer and TNM<Ⅳ(HR=0.218), with non-esophageal involvement all around(HR=0.384), with TNM<Ⅳ and non-esophageal involvement all around(HR=0.197), and with TNM<Ⅳ and non-ulcer type(HR=0.266,P<0.05). Conclusion Compared to patients with esophageal cancer treated with sequential chemoradiotherapy, patients treated with concurrent chemoradiotherapy have higher CR rate and long-term survival rate. Patients with TNM<Ⅳ, midpiece tumor location, non-esophageal involvement all around and non-ulcer type esophageal are the superior population for concurrent chemoradiotherapy.